Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Chimeric spike mRNA vaccines protect against Sarbecovirus challenge in mice
David R. Martinez, Alexandra Schäfer, Sarah R. Leist, et al.
Science (2021) Vol. 373, Iss. 6558, pp. 991-998
Open Access | Times Cited: 177

Showing 101-125 of 177 citing articles:

Antibody-mediated broad sarbecovirus neutralization through ACE2 molecular mimicry
Young‐Jun Park, Anna De Marco, Tyler N. Starr, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 17
Looking to the future: is a universal coronavirus vaccine feasible?
Vipin M. Vashishtha, Puneet Kumar
Expert Review of Vaccines (2021) Vol. 21, Iss. 3, pp. 277-280
Open Access | Times Cited: 17
Protective Efficacy of Rhesus Adenovirus COVID-19 Vaccines against Mouse-Adapted SARS-CoV-2
Lisa H. Tostanoski, Lisa E. Gralinski, David R. Martinez, et al.
Journal of Virology (2021) Vol. 95, Iss. 23
Open Access | Times Cited: 16
Influenza viruses and coronaviruses: Knowns, unknowns, and common research challenges
Olivier Terrier, Mustapha Si‐Tahar, Mariette Ducatez, et al.
PLoS Pathogens (2021) Vol. 17, Iss. 12, pp. e1010106-e1010106
Open Access | Times Cited: 16
Chimeric mRNA-based COVID-19 vaccine induces protective immunity against Omicron and Delta variants
Qidong Hu, Ying Zhao, Namir Shaabani, et al.
Molecular Therapy — Nucleic Acids (2022) Vol. 30, pp. 465-476
Open Access | Times Cited: 11
Rational design of a booster vaccine against COVID-19 based on antigenic distance
Ye‐Fan Hu, Terrence Tsz‐Tai Yuen, Huarui Gong, et al.
Cell Host & Microbe (2023) Vol. 31, Iss. 8, pp. 1301-1316.e8
Open Access | Times Cited: 6
Possible Targets of Pan-Coronavirus Antiviral Strategies for Emerging or Re-Emerging Coronaviruses
Xue Li, Liying Zhang, Si Chen, et al.
Microorganisms (2021) Vol. 9, Iss. 7, pp. 1479-1479
Open Access | Times Cited: 14
One dose of COVID-19 nanoparticle vaccine REVC-128 protects against SARS-CoV-2 challenge at two weeks post-immunization
Maggie Gu, Jonathan L. Torres, Yijia Li, et al.
Emerging Microbes & Infections (2021) Vol. 10, Iss. 1, pp. 2016-2029
Open Access | Times Cited: 14
Containment strategies for COVID-19 in India: lessons from the second wave
Purva Asrani, Keshav Tiwari, Mathew Suji Eapen, et al.
Expert Review of Anti-infective Therapy (2022) Vol. 20, Iss. 6, pp. 829-835
Closed Access | Times Cited: 10
Development of a thermostable SARS-CoV-2 variant-based bivalent protein vaccine with cross-neutralizing potency against Omicron subvariants
Rui Wang, Xun Huang, Tian-Shu Cao, et al.
Virology (2022) Vol. 576, pp. 61-68
Open Access | Times Cited: 10
Extremely potent pan-sarbecovirus neutralizing antibodies generated by immunization of macaques with an AS03-adjuvanted monovalent subunit vaccine against SARS-CoV-2
Yupeng Feng, Meng Yuan, John M. Powers, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 5
A potential silver lining of delaying the second dose
David R. Martinez, Eng Eong Ooi
Nature Immunology (2022) Vol. 23, Iss. 3, pp. 349-351
Open Access | Times Cited: 9
Nucleoside modifications of in vitro transcribed mRNA to reduce immunogenicity and improve translation of prophylactic and therapeutic antigens
Mohamad‐Gabriel Alameh, Drew Weissman
Elsevier eBooks (2022), pp. 141-169
Closed Access | Times Cited: 9
SARS-CoV-2 Neutralization by Cell Membrane-Coated Antifouling Nanoparticles
Hao Chen, Xilin Xiong, Yuan Huang, et al.
ACS Applied Bio Materials (2024) Vol. 7, Iss. 2, pp. 909-917
Closed Access | Times Cited: 1
Quantifying the impact of a broadly protective sarbecovirus vaccine in a future SARS-X pandemic
Charles A. Whittaker, Gregory Barnsley, Daniela Olivera Mesa, et al.
medRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 1
Pan-beta-coronavirus subunit vaccine prevents SARS-CoV-2 Omicron, SARS-CoV, and MERS-CoV challenge
Gang Wang, Abhishek Kumar Verma, Xiao‐Qing Guan, et al.
Journal of Virology (2024) Vol. 98, Iss. 9
Closed Access | Times Cited: 1
Bivalent norovirus mRNA vaccine elicits cellular and humoral responses protecting human enteroids from GII.4 infection
Elena N. Atochina‐Vasserman, Lisa C. Lindesmith, Carmen Mirabelli, et al.
npj Vaccines (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 1
A Cap-Optimized mRNA Encoding Multiepitope Antigen ESAT6 Induces Robust Cellular and Humoral Immune Responses Against Mycobacterium tuberculosis
Alena Kozlova, Ildus Pateev, Galina Shepelkova, et al.
Vaccines (2024) Vol. 12, Iss. 11, pp. 1267-1267
Open Access | Times Cited: 1
A trivalent mucosal vaccine encoding phylogenetically inferred ancestral RBD sequences confers pan-Sarbecovirus protection in mice
James Brett Case, Shilpa Sanapala, Carly Dillen, et al.
Cell Host & Microbe (2024)
Open Access | Times Cited: 1
Structural characterization of human monoclonal antibodies targeting uncommon antigenic sites on spike glycoprotein of SARS-CoV
Naveenchandra Suryadevara, Nurgun Kose, Sandhya Bangaru, et al.
Journal of Clinical Investigation (2024) Vol. 135, Iss. 3
Open Access | Times Cited: 1
SARS-CoV-2 vaccine-induced antibody and T cell response in SARS-CoV-1 survivors
Li‐Jun Duan, Xiaoming Cui, Ka-Li Zhu, et al.
Cell Reports (2022) Vol. 40, Iss. 9, pp. 111284-111284
Open Access | Times Cited: 8
Structural analysis of Plasmodium falciparum ookinete surface antigen Pfs28 relevant for malaria vaccine design
N. Shukla, Wai Kwan Tang, Niraj H. Tolia
Scientific Reports (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 8
Targeting spike glycans to inhibit SARS-CoV2 viral entry
Alex J. Guseman, Linda J. Rennick, Sham Nambulli, et al.
Proceedings of the National Academy of Sciences (2023) Vol. 120, Iss. 38
Open Access | Times Cited: 4
A broad and potent neutralization epitope in SARS-related coronaviruses
Meng Yuan, Xueyong Zhu, Wanting He, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 7
Inactivated SARS-CoV-2 Vaccine Shows Cross-Protection against Bat SARS-Related Coronaviruses in Human ACE2 Transgenic Mice
Meiqin Liu, Ren-Di Jiang, Jing Guo, et al.
Journal of Virology (2022) Vol. 96, Iss. 8
Open Access | Times Cited: 7

Scroll to top